HH

Hok Hei Tam

Senior Principal @ Flagship Pioneering | CTO @ Montai Therapeutics

Cambridge, Massachusetts

Invests in

Stages:

  • Min Investment:

    $500,000.00
  • Max Investment:

    $15,000,000.00
  • Target Investment:

    $7,000,000.00

Education

Work Experience

  • Senior Principal

    2023

  • Principal

    2021 - 2023

  • Senior Associate

    2019 - 2021

    Co-Founder of Senda Biosciences

  • Associate

    2017 - 2019

    Co-Founder of FL62 and FL65.

  • CTO

    2019

2020 - 2023

  • Acting CTO

    2020 - 2023

VL39

2017 - 2017

  • Scientific Consultant

    2017 - 2017

Inari Agriculture

2017 - 2017

  • Bioinformatics Consultant

    2017 - 2017

2012 - 2017

  • PhD Candidate

    2012 - 2017

    Ph. D. in Chemical Engineering with a Minor in Machine Learning Advisor: Dr. Daniel Anderson Committee: Dr. Bob Langer and Dr. Angela Koehler At the Anderson Lab, I developed a vaccine dosing scheme that leads to >10-fold improvement in antibody production, leading to a first-author publication in the Proceedings of the National Academy of Science. I also created statistical methods and software to analyze the effects of novel materials on fibrosis, leading to 4 publications in top journals: Nature Medicine, Nature Biotechnology, and Nature Materials. Furthermore, I developed novel conjugates for siRNA delivery to various tumors, leading to a Best Paper in Section award at the largest Chemical Engineering conference (AIChE) and publications in preparation. Work in my Ph.D. has contributed to two venture-backed companies: Sigilon and Verseau Therapeutics.

  • Entrepreneurial Fellow

    2017 - 2017

    As an entrepreneurial fellow, I explored new areas of science to generate ideas for first-in-class life-sciences companies.

Sana PCHR Lebanon

2014 - 2017

  • Project Lead/Developer

    2014 - 2017

    The PCHR Lebanon project developed a portable patient-centric electronic health record system with decision support features that was deployed to 10 primary healthcare centers throughout Lebanon to assist in the treatment of Syrian refugees with chronic disease. It received a Research for Health in Humanitarian Crises grant from ELRHA. This project was also a finalist in the Applied Innovation Institute's University Mobile Challenge in 2015

Sigilon Therapeutics, Inc.

2016 - 2017

  • Scientific Consultant

    2016 - 2017

  • Scientific Consultant

    2016 - 2016